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reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and listings that follow, COSTART terminology has been used to classify reported adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. Adverse events associated with discontinuation of treatment: In two placebo-controlled studies of up to 5 weeks duration among children with ADHD, 2.4% (10/425) of ADDERALL XR® treated patients discontinued due to adverse events (including 3 patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/259) receiving placebo. The most frequent adverse events associated with discontinuation of ADDERALL XR® in controlled and uncontrolled, multiple-dose clinical trials of pediatric patients (N=595) are presented below. Over half of these patients were exposed to ADDERALL XR® for 12 months or more. Adverse event % of pediatric patients discontinuing (n=595) 2.9 In one placebo-controlled 4-week study among adults with ADHD, patients who discontinued treatment due to adverse events among ADDERALL XR®-treated patients (N=191) were 3.1% (n=6) for nervousness including anxiety and irritability, 2.6% (n=5) for insomnia, 1% (n=2) each for headache, palpitation, and somnolence; and, 0.5% (n=1) each for ALT increase, agitation, chest pain, cocaine craving, elevated blood pressure, and weight loss.
Adverse events occurring in a controlled trial: Adverse events reported in a 3-week clinical trial of pediatric patients and a 4-week clinical trial in adults treated with ADDERALL XR® or placebo are presented in the tables below. The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied. Note: The following events did not meet the criterion for inclusion in Table 2 but were reported by 2% to 4% of adult patients receiving ADDERALL XR® with a higher incidence than patients receiving placebo in this study: infection, photosensitivity reaction, constipation, tooth disorder, emotional lability, libido decreased, somnolence, speech disorder, palpitation, twitching, dyspnea, sweating, dysmenorrhea, and impotence. 'included doses up to 60 mg. The following adverse reactions have been associated with amphetamine use: Cardiovascular: Palpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use. Central Nervous System: Psychotic episodes at recommended doses, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, depression, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome, seizures, stroke. Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects. Allergic: Urticaria. Endocrine: Impotence, changes in libido.
DRUG ABUSE AND DEPENDENCE
ADDERALL XR® is a Schedule II controlled substance. Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines may include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.
OVERDOSAGE
Individual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses. Symptoms: Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma. Treatment: Consult with a Certified Poison Control Center for up to date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication. The prolonged release of mixed amphetamine salts from ADDERALL XR® should be considered when treating patients with overdose. Dispense in a tight, light-resistant container as defined in the USP. Store at 25° C (77° F 
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efficacy ot SEROQUEL in anrte bioolar mania was established in two 3-week monotherapy trials and one 3-week adjunct therapy trial ot bipolar I patients initially hospitalized lor up to 7 days for acute mania Effectiveness for mire than 3 weeks his not been systematically evaluated in clinical trials Therefore the physician who elects to use SEROQUEL for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual rjltjent Sthlzoghrenla' SEROQUEL is indicated for the treatment of schizophrenia The efficacy of SEROQUEL in schizophrenia was established in short-term 16-week) controlled trials of schizophrenic inoatients In these studies, the most commonly observed adverse events associated with the use of SEROQUEL (incidence of 5% or greater) and observed at a rate on SEROQUEL at least twice that ol placebo were somnolence (34%), dry mouth ( In schizophrenia trials the proportions of patients meeting a weight gain criterion of >7% of body weight were compared in a pool of four 3-to 6-week placebo-controlled clinical tnals, revealing a statist!-calty significantly greater incidence of weight gain lor SEROQUEL (23%) compared to placebo (6%), In mania monotherapy trials the proportions of patients meeting the same weight gam criterion were 21% compared to 7% "»Placebo and in mama adiinct therapy trials the proportion ot patients meeting the same weight criterion were 13* compared to 4% for placebo. Laboratory Changes: An assessment of the ptemarketing experience tor SEROOUEL suggested that it is associated with asymptomatic increases in SGPT and increases in both total chok t " < 1 rt triglycendes (see PRECAUTIONS). An assessment of nematological parameters in short-term, placebocontrolled tnals revealed no clinically important differences between SEROOUEL and placebo, ECG Ctaio.es: 5 ™ 5 ! ! ™ P comparisons lor pooled placebo-controlled trials revealed no statistically significant SEROQUEL/placebo differences in the proportions of patients experiencing potentially important changes in ECG Parameters, including QT, QTc, and PR intervals. However, the proportions of patients meeting the criteria fortachy-» * were compared"four 3-to 6-week placebo-controlled clinical rials for the treatment of schizophrenia ' « * » » ' % i 4 ' 3 ? 9 ) incidence for SEROQUEL compared to 0.6% (1/156) incidence for placebo. In acute m 0 ™ m f f i L D ' P°l a r ™ " " * ™ proportions of patients meeting the criteria for tachycardia was 0.5% ( ™ 2 ) «* SEROQUEL compared to 0% (0/178) incidence tor placebo. In acute bipolar mania (adjunct trials the Proportions of patients meeting the same ontena was 0.6% (1/166) for SEROQUEL compared to 0% (0/171) mos e n t t .™ P'aeeoo. OEHOQUEL use was associated with a mean increase in heart rate assessed by ECG, of 7 beats Per minute compared to a mean increase ot 1 beat per minute among placebo patients. This slight tendency to tachy- demonstrated a dose-related decrease in total and tree thyroxine (T4) of approximately 20% at the hipher end of the therapeutic dose range and was maximal in the first two to four weeks ot treatmer« and maintamed wlhout adaptation or progression during more chronic therapy. Generally, these changes were of no clinical signrficance and TSH was unchanged in most patients, and levels ol fBG were unchanOed. In nearly all cases, cessation of SEROQUEL treatment was associated wlh a reversal of the effects on total and tree T4, irrespective of the duration of treatment About 0.4% I1M791) of SEROQUEL patients did experience TSH increases in monotherapy studies, Sk of the patients with TSH increases needed replacement thyroid treatment. In the mania adjunct studies. where SEROQUEL was added to litliium or divalproate, 12% (24/196) of SEROQUEL treated patients compared to 7% (15/203) of placebo treated patients had elevated TSH levels, Ofthe SEROOUEL treated patients with elevated TSH levels, 3 had simultaneous low free T4 levels. Cholesterol and Trlglvcerlte Elevations: In schizophrenia trials, SEROOUEL-treated patients had increases from baseline in cholesterol and triglpride of 11% and 17%, respeCtrvel>, compared toslirjht decreases for placebo patients. These changes were only weakly related to the increases it weight observed in SEROOUEL-treated patients, Hyp.rprolactinemla: Although an elevation of prol a * levels was not demonstrated in clinical trials with SEROOUEL, increased prolactin levels were observed in rat studies wlh this compound, and were associated wlh an increase in mammary gland neoplasia in rats (see Carcioooenesis). Tissue culture experiments indicate that approximate*/ one-third of human breast cancers are prol a * dependent it * , a factor of potential importance if the prescription of these drugs is contempMed in a patient whh previously detected breast cancer. Although disturbances such as gaiactorrhea, amenorrhea, gynecomas*, and impotence have been reported w«h prolactin-elevating compounds, the clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class ol drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Transimlmse Elivitions: Asymptomatic, transient and reversible elevations in serum transaminases (primarily ALT) have been reported. In scheophrenia trials, the proportions of patients with transaminase elevations ol > 3 times the upper limits of the normalreference range in a pool of 3-to 6-week placebo-controlled trials were approximately 6% lor SEROQUEL compared to 1% tor placebo. In acute bipolar mania trials, the proportions of patients with transaminase elevations of > 3 times the upper limits of the normal reference range in a pool ol 3-to 12-week placebo-controlled trials were approximately 1% for both SEROQUEL and placebo. These hepatic enzyme elevations usually occurred within the first 3 weeks of drug treatment and promply returned to pre-study levels with ongoing treatment wlh SEROQUEL Potential lot Cognitive and Motor Impairment Somnolence was a common^ reported adverse event reported in patients treated with SEROOUEL especially during the 3-5 day period of initial dose-titration. In schizophrenia trials, somnolence was reported in 11% ot patients on SEROOUEL compared to 11% ol placebo patients. In acute bipolar mania trials using SEROQUEL as monotherapy, somnolence was reported in 16% ot patients on SEROQUEL compared to 4% ol placebo patients. In acute bipolar mania trials using SEROQUEL as adjunct therapy, somnolence was reported in 34% ol patients on SEROQUEL compared to 9% ot placebo patients. Since SEROQUEL has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that SEROOUEL therapy does not atfectthem adversely. Priapism: One case of priapism in a patient receiving SEROQUEL has been reported prior to market introduction. While a causal relationship to use of SEROQUEL has not been established, other drugs whh alpha-adrenergic blocking effects have been reported to induce priapism, and it i s possible that SEROQUEL may share this capacity. Severe priapism may require surgical intervention. Body Temperature Regulation: Although not reported wJh SEROQUEL, disruption ol the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing SEROOUEL tor patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g, exercising strenuously, exposure to extreme heat, receiving concomitant medication wlh anticholinergic activity, or being subjeel to dehydration. Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL.
There have been reports of diabetes mellitus and hyperglycennia-related adverse events associated with the use of atypical antipsychotics, including SEROQUEL.
The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia, and weight gain. 
For Bipolar Manir
Abilify is indicated for the treatment of schizophrenia and acute manic and mixed episodes associated with bipolar disorder.
IMPORTANT SAFETY INFORMATION
As with all antipsychotic medications, a rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported. As with all antipsychotic medications, prescribing should be consistent with the need to minimize the risk of tardive dyskinesia (TD).
Hyperglycemia, including some serious cases ranging from ketoacidosis to death, has been reported in patients treated with atypical antipsychotics. Abilify was not included in epidemiologic studies suggesting this risk; therefore the risk of hyperglycemia with Abilify is not known. However, there have been few reports of hyperglycemia in patients treated with Abilify. Patients should be appropriately tested before and monitored during treatment.
Abilify may be associated with orthostatic hypotension and should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.
As with other antipsychotic drugs, Abilify should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold. Seizures occurred in 0.3% of bipolar patients treated with Abilify in placebo-controlled trials.
Patients should not drive or operate heavy machinery until they are certain Abilify does not affect them adversely.
Commonly observed adverse events reported with Abilify in 3-week bipolar mania trials at a >5% incidence for Abilify and at a rate at least twice the rate of placebo include, respectively, akathisia (15% vs 4%), constipation (13% vs 6%), and accidental injury (6% vs 3%).
Treatment-emergent adverse events reported with Abilify in short-term trials at an incidence > 10% and greater than placebo, respectively, include headache (31% vs 26%), agitation (25% vs 24%), anxiety (20% vs 17%), insomnia (20% vs 15%), nausea (16% vs 12%), dyspepsia (15% vs 13%), somnolence (12% vs 8%), akathisia (12% vs 5%), lightheadedness (11% vs 8%), vomiting (11% vs 6%), and constipation (11% vs 7%).
The adverse events reported in a 26-week, double-blind schizophrenia trial comparing Abilify and placebo were generally consistent with those reported in the short-term, placebo-controlled schizophrenia trials, except for a higher incidence of tremor: 9% for Abilify vs 1% for placebo. In this study the majority of the cases of tremor were of mild intensity (9/13 mild and 4/13 moderate), occurred early in therapy (9/13 s49 days), and were of limited duration (9/13 <10 days). Tremor infrequently led to discontinuation (<1%) of Abilify. In addition, in a long-term (52-week), active-controlled study, the incidence of tremor for Abilify was 4%. PHARMACOLOGY) . However, the effectiveness of ABILIFY for longer-term use, that is, for more than 3 weeks of treatment of an acute episode, and for prophylactic use in mania, has not been established in controlled clinical trials. Therefore, physicians who elect to use ABILIFY for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
CONTRAINDICATIONS
ABILIFY is contraindicated in patients with a known hypersensitivity to the product.
WARNINGS Neuroleplic Malignant Syndrome (NMS)
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including aripiprazoie. Two possible cases of NMS occurred during aripiprazoie treatment in the premarketing worldwide clinical database. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Tardlve Dysklnesla A syndrome of potentially Irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesla is unknown. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient Increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and, thereby, may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, ABILIFY should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on ABILIFY, drug discontinuation should be considered. However, some patients may require treatment with ABILIFY despite the presence of the syndrome.
Hyperglycemia and Diabetes Mellltus
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia in patients treated with ABILIFY. Although fewer patients have been treated with ABILIFY, it is not known if this more limited experience is the sole reason for the paucity of such reports. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies which did not include ABILIFY suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics included in these studies. Because ABILIFY was not marketed at the time these studies were performed, it is not known if ABILIFY is associated with this increased risk. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
PRECAUTIONS General Orthostatic Hypotension
Aripiprazoie may be associated with orthostatic hypotension, perhaps due to its a,-adrenergic receptor antagonism. The incidence of orthostatic hypotension associated events from five short-term, placebo-controlled trials in schizophrenia (n=926) on ABILIFY included: orthostatic hypotension (placebo 1%, aripiprazoie 1.9%), orthostatic lightheadedness (placebo 1 %, aripiprazoie 0.9%), and syncope (placebo 1 %, aripiprazoie 0.6%). The incidence of orthostatic hypotension associated events from short-term, placebo-controlled trials in bipolar mania (n=597) on ABILIFY included: orthostatic hypotension (placebo 0%, aripiprazoie 0.7%), orthostatic lightheadedness (placebo 0.5%, aripiprazoie 0.5%), and syncope (placebo 0.9%, aripiprazoie 0.5%). The incidence of a significant orthostatic change in blood pressure (defined as a decrease of at least 30 mmHg in systolic blood pressure when changing from a supine to standing position) for aripiprazoie was not statistically different from placebo (in schizophrenia: 14% among aripiprazole-treated patients and 12% among placebo-treated patients and in bipolar mania: 3% among aripiprazole-treated patients and 2% among placebo-treated patients). Aripiprazoie should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizure Seizures occurred in 0.1% (1/926) of aripiprazole-treated patients with schizophrenia in short-term, placebo-controlled trials. In short-term, placebo-controlled clinical trials of patients with bipolar mania, 0.3% (2/597) of aripiprazole-treated patients and 0.2% (1/436) placebo-treated patients experienced seizures. As with other antipsychotic drugs, aripiprazoie should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Potential for Cognitive and Motor Impairment in short-term, placebo-controlled trials of schizophrenia, somnolence was reported in 11% of patients on ABILIFY compared to 8% of patients on placebo; somnolence led to discontinuation in 0.1 % (1/926) of patients with schizophrenia on ABILIFY in short-term, placebo-controlled trials. In short-term, placebo-controlled trials of bipolar mania, somnolence was reported in 14% of patients on ABILIFY compared to 7% of patients on placebo, but did not lead to discontinuation of any patients with bipolar mania. Despite the relatively modest increased incidence of somnolence compared to placebo, ABILIFY, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ABILIFY does not affect them adversely.
Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing aripiprazoie for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.
Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia.
Aripiprazoie and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia (see
PRECAUTIONS: Use in Patients witn Concomitant Illness). Suicide
The possibility of a suicide attempt is inherent in psychotic illnesses and bipolar disorder, and close supervision of highrisk patients should accompany drug therapy. Prescriptions for ABILIFY (aripiprazoie) should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.
Use in Patients witn Concomitant Illness Safety Experience in Elderly Patients with Psychosis Associated with Alzheimer's Disease:
In a flexible dose (2 to 15 mg/day), 10-week, placebo-controlled study of aripiprazoie in elderly patients (mean age: 81.5 years; range: 56 to 95 years) with psychosis associated with Alzheimer's dementia, 4 of 105 patients (3.8%) who received ABILIFY died compared to no deaths among 102 patients who received placebo during or within 30 days after termination of the doubleblind portion of the study. Three of the patients (age 92,91, and 87 years) died following the discontinuation of ABILIFY in the double-blind phase of the study (causes of death were pneumonia, heart failure, and shock). The fourth patient (age 78 years) died following hip surgery while in the double-blind portion of the study. The treatment-emergent adverse events that were reported at an incidence of >5% and having a greater incidence than placebo in this study were accidental injury, somnolence, and bronchitis. Eight percent of the ABILIFY-treated patients reported somnolence compared to one percent of placebo patients. In a small pilot, open-label, ascending-dose, cohort study (n=30) in elderly patients with dementia, ABILIFY was associated in a dose-related fashion with somnolence. The safety and efficacy of ABILIFY in the treatment of patients with psychosis associated with dementia have not been established. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised, particularly for the emergence of difficulty swallowing or excessive somnolence, which could predispose to accidental injury or aspiration. Clinical experience with ABILIFY in patients with certain concomitant systemic illnesses (see CLINICAL PHARMACOLOGY: Special Populations: Renal Impairment and Hepatic Impairment in Full Prescribing Information) is limited. ABILIFY has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies.
Information for Patients:
Physicians are advised to consult full prescribing information to review issues to be discussed wtih patients for whom they prescribe ABILIFY. Drug-Drug Interactions: Given the primary CNS effects of aripiprazoie, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol. Due to its a,-adrenergic receptor antagonism, aripiprazoie has the potential to enhance the effect of certain antihypertensive agents.
Potential for Other Drugs to Affect ABIUFY:
Aripiprazoie is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazoie also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazoie with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely. Both CYP3A4 and CYP2D6 are responsible for aripiprazoie metabolism. Agents that induce CYP3A4 (e.g., carbamazepine) could cause an increase in aripiprazoie clearance and lower blood levels. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., quinidine, fluoxetine, or paroxetine) can inhibit aripiprazoie elimination and cause increased blood levels. Ketoconazole. Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazoie increased the AUC of aripiprazoie and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When concomitant administration of ketoconazole with aripiprazoie occurs, aripiprazoie dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; weaker inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazoie dose should then be increased. Quinidine: Coadministration of a 10-mg single dose of aripiprazoie with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazoie by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazoie dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazoie occurs. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazoie dose should then be increased. Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazoie (30 mg OD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazoie and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazoie therapy, aripiprazoie dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, aripiprazoie dose should then be reduced. No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazoie (see CLINICAL
PHARMACOLOGY: Drug-Drug Interactions in Full Prescribing Information). Potential for ABILIFY to Affect Other Drugs:
Aripiprazoie is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10-to 30-mg/day doses of aripiprazoie had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates. Additionally, aripiprazoie and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro (see CLINICAL PHARMACOLOGY: Drug-Drug Interactions). Alcohol: There was no significant difference between aripiprazoie coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects. As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY.
Carcinogenesis, Mutagenesis, Impairment of Fertility: (Please See Full Prescribing Information). Pregnancy Pregnancy Category C
In animal studies, aripiprazoie demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits. Pregnant rats were treated with oral doses of 3,10, and 30 mg/kg/day (1, 3, and 10 times the maximum recommended human dose [MRHDJ on a mg/m ! basis) of aripiprazoie during the period of organogenesis. Gestation was slightly prolonged at 30 mg/kg. Treatment caused a slight delay in fetal development, as evidenced by decreased fetal weight (30 mg/kg), undescended testes (30 mg/kg), and delayed skeletal ossification (10 and 30 mg/kg). There were no adverse effects on embryofetal or pup survival. Delivered offspring had decreased bodyweights (10 and 30 mg/kg), and increased incidences of hepatodiaphragmatic nodules and diaphragmatic hernia at 30 mg/kg (the other dose groups were not examined for these findings). (A low incidence of diaphragmatic hernia was also seen in the fetuses exposed to 30 mg/kg.) Postnatally, delayed vaginal opening was seen at 10 and 30 mg/kg and impaired reproductive performance (decreased fertility rate, corpora lutea, implants, and live fetuses, and increased post-implantation loss, likely mediated through effects on female offspring) was seen at 30 mg/kg. Some maternal toxicity was seen at 30 mg/kg, however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity. Pregnant rabbits were treated with oral doses of 10,30, and 100 mg/kg/day (2,3, and 11 times human exposure at MRHD based on AUC and 6,19, and 65 times the MRHD based on mg/m 2 ) of aripiprazoie during the period of organogenesis. Decreased maternal food consumption and increased abortions were seen at 100 mg/kg. Treatment caused increased fetal mortality (100 mg/kg), decreased fetal weight (30 and 100 mg/kg), increased incidence of skeletal abnormality (fused sternebrae at 30 and 100 mg/kg) and minor skeletal variations (100 mg/kg). In a study in which rats were treated with oral doses of 3,10, and 30 mg/kg/day (1, 3, and 10 times the MRHD on a mg/m 2 basis) of aripiprazoie perinatally and postnatally (from day 17 of gestation through day 21 postpartum), slight maternal toxicity and slightly prolonged gestation were seen at 30 mg/kg. An increase in stillbirths, and decreases in pup weight (persisting into adulthood) and survival, were seen at this dose. There are no adequate and well-controlled studies in pregnant women. It is not known whether aripiprazoie can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Aripiprazoie should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Labor and Delivery
The effect of aripiprazoie on labor and delivery in humans is unknown.
Nursing Mothers
Aripiprazoie was excreted in milk of rats during lactation. It is not known whether aripiprazoie or its metabolites are excreted in human milk. It is recommended that women receiving aripiprazoie should not breast-feed. Pediatric Use Safety and effectiveness in pediatric and adolescent patients have not been established.
Geriatric Use
Of the 7951 patients treated with aripiprazoie in premarketing clinical trials, 991 (12%) were >65 years old and 789 (10%) were 275 years old. The majority (88%) of the 991 patients were diagnosed with dementia of the Alzheimer's type. Placebo-controlled studies of aripiprazoie in schizophrenia or bipolar mania did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.There was no effect of age on the pharmacokinetics of a single 15-mg dose of aripiprazoie. Aripiprazoie clearance was decreased by 20% in elderly subjects (>65 years) compared to younger adult subjects (18 to 64 years), but there was no detectable effect of age in the population pharmacokinetic analysis in schizophrenia patients. Studies of elderly patients with psychosis associated with Alzheimer's disease have suggested that there may be a different tolerability profile in this population compared to younger patients with schizophrenia (see PRECAUTIONS: Use in Patients with Concomitant Illness). The safety and efficacy of ABILIFY in the treatment of patients with psychosis associated with Alzheimer's disease has not been established. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised. https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852900002182 Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 15 Oct 2018 at 18:15:58, subject to the Cambridge Core terms of use, available at ADVERSE REACTIONS Aripiprazole has been evaluated for safety in 7951 patients who participated in multiple-dose, premarketing trials in schizophrenia, bipolar mania, and dementia of the Alzheimer's type, and who had approximately 5235 patient-years of exposure. A total of 2280 aripiprazole-treated patients were treated for at least 180 days and 1558 aripiprazole-treated patients had at least 1 year of exposure. The conditions and duration of treatment with aripiprazole included (in overlapping categories) double-blind, comparative and noncomparative open-label studies, inpatient and outpatient studies, fixed-and flexible-dose studies, and short-and longer-term exposure. Adverse events during exposure were obtained by collecting volunteered adverse events, as well as results of physical examinations, vital signs, weights, laboratory analyses, and ECG. Adverse experiences were recorded by clinical investigators using terminology of their own choosing. In the tables and tabulations that follow, modified COSTART dictionary terminology has been used initially to classify reported adverse events into a smaller number of standardized event categories, in order to provide a meaningful estimate of the proportion of individuals experiencing adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. There was no attempt to use investigator causality assessments; i.e., all reported events are included. The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatment, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the adverse event incidence in the population studied.
Adverse Findings Observed in Short-Term, Placebo-Controlled Trials of Patients with Schizophrenia
The following findings are based on a pool of five placebo-controlled trials (four 4-week and one 6-week) in which aripiprazole was administered in doses ranging from 2 to 30 mg/day.
Adverse Events Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials
Overall, there was no difference in the incidence of discontinuation due to adverse events between aripiprazole-treated (7%) and placebo-treated (9%) patients. The types of adverse events that led to discontinuation were similar between the aripiprazole and placebo-treated patients.
Adverse Findings Observed in Short-Term, Placebo-Controlled Trials of Patients with Bipolar Mania
The following findings are based on a pool of 3-week, placebo-controlled bipolar mania trials in which aripiprazole was administered at doses of 15 or 30 mg/day.
Adverse Events Associated with Discontinuation of Treatment in Snort-Term, Placebo-Controlled Trials
Overall, in patients with bipolar mania, there was no difference in the incidence of discontinuation due to adverse events between aripiprazole-treated (11%) and placebo-treated (9%) patients. The types of adverse events that led to discontinuation were similar between the aripiprazole and placebo-treated patients.
Commonly Observed Adverse Events in Short-Term, Placebo-Controlled Trials of Patients with Bipolar Mania
Commonly observed adverse events associated with the use of aripiprazole in patients with bipolar mania (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) are shown in Table 1 . There were no adverse events in the short-term trials of schizophrenia that met these criteria. Adverse Events Occurring at an Incidence of 2% or More Among Aripiprazole-Treated Patients and Greater than Placebo in Short-Term, Placebo-Controlled Trials Treatment-emergent adverse events that occurred during acute therapy (up to 6 weeks in schizophrenia and up to 3 weeks in bipolar mania), including only those events that occurred in 2% or more of patients treated with aripiprazole (doses >2 mg/day) and for which the incidence in patients treated with aripiprazole was greater than the incidence in patients treated with placebo in the combined dataset were: Body as a Whole-headache, asthenia, accidental injury, peripheral edema; Cardiovascular System-hypertension; Digestive System-nausea, dyspepsia, vomiting, constipation; Musculoskeletal System-myalgia; Nervous System-agitation, anxiety, insomnia, somnolence, akathisia, lightheadedness, extrapyramidal syndrome, tremor, increased salivation; Respiratory System-pharyngitis, rhinitis, coughing; Special Senses-blurred vision. An examination of population subgroups did not reveal any clear evidence of differential adverse event incidence on the basis of age, gender, or race.
Dose-Related Adverse Events Schizophrenia
Dose response relationships for the incidence of treatment-emergent adverse events were evaluated from four trials in patients with schizophrenia comparing various fixed doses (2,10,15,20, and 30 mg/day} of aripiprazole to placebo. This analysis, stratified by study, indicated that the only adverse event to have a possible dose response relationship, and then most prominent only with 30 mg, was somnolence (placebo, 7.7%; 15 mg, 8.7%; 20 mg, 7.5%; 30 mg, 15.3%).
Extrapyramidal Symptoms
In the short-term, placebo-controlled trials of schizophrenia, the incidence of reported EPS for aripiprazole-treated patients was 6% vs. 6% for placebo. In the short-term, placebo-controlled trials in bipolar mania, the incidence of reported EPSrelated events excluding events related to akathisia for aripiprazole-treated patients was 17% vs. 12% for placebo. In the short-term, placebo-controlled trials in bipolar mania, the incidence of akathisia-related events for aripiprazole-treated patients was 15% vs. 4% for placebo. Objectively collected data from those trials was collected on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias). In the schizophrenia trials, the objectively collected data did not show a difference between aripiprazole and placebo, with the exception of the Barnes Akathisia Scale (aripiprazole, 0.08; placebo, -0.05). In the bipolar mania trials, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a significant difference between aripiprazole and placebo (aripiprazole, 0.61; placebo, 0.03 and aripiprazole, 0.25; placebo, -0.06) . Changes in the Assessments of Involuntary Movement Scales were similar for the aripiprazole and placebo groups. Similarly, in a longterm (26-week), placebo-controlled trial of schizophrenia, objectively collected data on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and the Assessments of Involuntary Movement Scales (for dyskinesias) did not show a difference between aripiprazole and placebo.
Laboratory Test Abnormalities
A between group comparison for 3-to 6-week, placebo-controlled trials revealed no medically important differences between the aripiprazole and placebo groups in the proportions of patients experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no aripiprazole/placebo differences in the incidence of discontinuations for changes in serum chemistry, hematology, or urinalysis. In a long-term (26-week), placebo-controlled trial there were no medically important differences between the aripiprazole and placebo patients in the mean change from baseline in prolactin, fasting glucose, triglyceride, HDL, LDL and total cholesterol
Weight Gain
In 4-to 6-week trials in schizophrenia, there was a slight difference in mean weight gain between aripiprazole and placebo patients (+0.7 kg vs. -0.05 kg, respectively), and also a difference in the proportion of patients meeting a weight gain criterion of >7% of body weight [aripiprazole (8%) compared to placebo (3%)]. In 3-week trials in mania, the mean weight gain for aripiprazole and placebo patients was 0.0 kg vs. -0.2 kg, respectively. The proportion of patients meeting a weight gain criterion of >7% of body weight was aripiprazole (3%) compared to placebo (2%). Table 2 provides the weight change results from a long-term (26-week), placebo-controlled study of aripiprazole, both mean change from baseline and proportions of patients meeting a weight gain criterion of >7% of body weight relative to baseline, categorized by BMI at baseline: Table 3 provides the weight change results from a long-term (52-week) study of aripiprazole, both mean change from baseline and proportions of patients meeting a weight gain criterion of >7% of body weight relative to baseline, categorized by BMI at baseline: 
ECG Changes
Between group comparisons for pooled, placebo-controlled trials in patients with schizophrenia, revealed no significant differences between aripiprazole and placebo in the proportion of patients experiencing potentially important changes in ECG parameters; in fact, within the dose range of 10 to 30 mg/day, aripiprazole tended to slightly shorten the QTt interval. Aripiprazole was associated with a median increase in heart rate of 4 beats per minute compared to a 1 beat per minute increase among placebo patients.
Additional Findings Observed in Clinical Trials Adverse Events in a Long-Term, Double-Blind, Placebo-Controlled Trial
The adverse events reported in a 26-week, double-blind trial comparing ABIUFY (aripiprazole) and placebo were generally consistent with those reported in the short-term, placebo-controlled trials, except for a higher incidence of tremor [9% (13/153) for ABIUFY vs. 1% (2/153) for placebo]. In this study, the majority of the cases of tremor were of mild intensity (9/13 mild and 4/13 moderate), occurred early in therapy (9/13 <49 days), and were of limited duration (9/13 <10 days). Tremor infrequently led to discontinuation (<1%) of ABILIFY, In addition, in a long-term (52-week), activecontrolled study, the incidence of tremor for ABILIFY was 4% (34/859).
Other Adverse Events Observed During the Premarketing Evaluation of Aripiprazole
Following is a list of modified COSTART terms that reflect treatment-emergent adverse events as defined in the introduction to the ADVERSE REACTIONS section reported by patients treated with aripiprazole at multiple doses >2 mg/day during any phase of a trial within the database of 7951 patients. All reported events are included except those already listed in other parts of the ADVERSE REACTIONS section, those considered in the WARNINGS or PRECAUTIONS, those event terms which were so general as to be uninformative, events reported with an incidence of <0.05% and which did not have a substantial probability of being acutely life-threatening, events that are otherwise common as background events, and events considered unlikely to be drug related. It is important to emphasize that, although the events reported occurred during treatment with aripiprazole, they were not necessarily caused by it. Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Body as a Whole: Frequent-flu syndrome, fever, chest pain, rigidity (including neck and extremity), neck pain, pelvic pain; Infrequent-face edema, suicide attempt, malaise, migraine, chills, photosensitivity, tightness (including abdomen, back, extremity, head, jaw, neck, and tongue), jaw pain, bloating, enlarged abdomen, chest tightness, throat pain; Rare -moniliasis, head heaviness, throat tightness, Mendelson's syndrome, heat stroke. Cardiovascular System: Frequent-tachycardia (including ventricular and supraventricular), hypotension, bradycardia; Infrequent-palpitation, hemorrhage, heart failure, myocardial infarction, cardiac arrest, atrial fibrillation, AV block, prolonged OT interval, extrasystoles, myocardial ischemia, deep vein thrombosis, angina pectoris, pallor, cardiopulmonary arrest, phlebitis; Rare -bundle branch block, atrial flutter, vasovagal reaction, cardiomegaly, thrombophlebitis, cardiopulmonary failure. Digestive System: Frequent -nausea and vomiting; Infrequent -increased appetite, dysphagia, gastroenteritis, flatulence, tooth caries, gastritis, gingivitis, gastrointestinal hemorrhage, hemorrhoids, gastroesophageal reflux, periodontal abscess, fecal incontinence, rectal hemorrhage, stomatitis, colitis, tongue edema, cholecystitis, mouth ulcer, oral moniliasis, eructation, fecal impaction, cholelithiasis; Rare -esophagitis, hematemesis, intestinal obstruction, gum hemorrhage, hepatitis, peptic ulcer, glossitis, melena, duodenal ulcer, cheilitis, hepatomegaly, pancreatitis. Endocrine System: Infrequent -hypothyroidism; Rare -goiter, hyperthyroidism. Hemic/Lymphatic System: Frequent -ecchymosis, anemia; Infrequent -hypochromic anemia, leukocytosis, leukopenia (including neutropenia), lymphadenopathy, eosinophilia, macrocytic anemia; Rare -thrombocythemia, thrombocytopenia, petechiae. Metabolic and nutritional Disorders: Frequent -weight loss, creatine phosphokinase increased, dehydration; Infrequent -edema, hyperglycemia, hypercholesteremia, hypokalemia, diabetes mellitus, hypoglycemia, hyperlipemia, SGPT increased, thirst, BUN increased, hyponatremia, SGOT increased, creatinine increased, cyanosis, alkaline phosphatase increased, bilirubinemia, iron deficiency anemia, hyperkalemia, hyperuricemia, obesity; Rare -lactic dehydrogenase increased, hypernatremia, gout, hypoglycemic reaction. Musculoskeletal System: Frequent -muscle cramp; Infrequent -arthralgia, myasthenia, arthrosis, bone pain, arthritis, muscle weakness, spasm, bursitis, myopathy; Rare -rheumatoid arthritis, rhabdomyolysis, tendonitis, tenosynovitis. Nervous System: Frequent -depression, nervousness, schizophrenic reaction, hallucination, hostility, confusion, paranoid reaction, suicidal thought, abnormal gait, manic reaction, delusions, abnormal dream; Infrequent -emotional lability, twitch, cogwheel rigidity, impaired concentration, dystonia, vasodilation, paresthesia, impotence, extremity tremor, hypesthesia, vertigo, stupor, bradykinesia, apathy, panic attack, decreased libido, hypersomnia, dyskinesia, manic depressive reaction, ataxia, visual hallucination, cerebrovascular accident, hypokinesia, depersonalization, impaired memory, delirium, dysarthria, tardive dyskinesia, amnesia, hyperactivity, increased libido, myoclonus, restless leg, neuropathy, dysphoria, hyperkinesia, cerebral ischemia, increased reflexes, akinesia, decreased consciousness, hyperestJiesia, slowed thinking; Rare -blunted affect, euphoria, incoordination, oculogyric crisis, obsessive thought, hypotonia, buccoglossal syndrome, decreased reflexes, derealization, intracranial hemorrhage. Respiratory System: Frequent-sinusitis, dyspnea, pneumonia, asthma; Infrequent-epistim, hiccup, laryngitis, aspiration pneumonia; Rare -pulmonary edema, increased sputum, pulmonary embolism, hypoxia, respiratory failure, apnea, dry nasal passages, hemoptysis. Skin and Appendages: Frequent-skin ulcer, sweating, dry skin; Infrequent-pruritus, vesiculobullous rash, acne, eczema, skin discoloration, alopecia, seborrhea, psoriasis: Rare -maculopapular rash, exfoliatlve dermatitis, urticaria. Special Senses: Frequent -conjunctivitis; Infrequent -ear pain, dry eye, eye pain, tinnitus, cataract, otitis media, altered taste, blepharitis, eye hemorrhage, deafness; Rare -diplopia, frequent blinking, ptosis, otitis externa, amblyopia, photophobia. Urogenital System: Frequent -urinary incontinence; Infrequent-urinary frequency, leukorrhea, urinary retention, cystitis, hematuria, dysuria, amenorrhea, vaginal hemorrhage, abnormal ejaculation, kidney failure, vaginal moniliasis, urinary urgency, gynecomastia, kidney calculus, albuminuria, breast pain, urinary burning; Rare-nocturia, polyuria, menorrhagia, anorgasmy, glycosuria, cervicitis, uterus hemorrhage, female lactation, urolithiasis, priapism.
Other Events Observed During the Postmarketing Evaluation of Aripiprazole
Voluntary reports of adverse events in patients taking aripiprazole that have been received since market introduction and not listed above that may have no causal relationship with the drug include rare occurrences of allergic reaction (e.g., anaphylactic reaction, angioedema, laryngospasm, pruritis, or urticaria).
DRUG ABUSE AND DEPENDENCE Controlled Substance
ABILIFY is not a controlled substance.
Abuse and Dependence
Aripiprazole has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence.
In physical dependence studies in monkeys, withdrawal symptoms were observed upon abrupt cessation of dosing. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ABILIFY misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).
OVERDOSAGE

Management of Overdosage
No specific information is available on the treatment of overdose with aripiprazole. An electrocardiogram should be obtained in case of overdosage and, if QTC interval prolongation is present, cardiac monitoring should be instituted.
Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.
Charcoal: In the event of an overdose of ABILIFY, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15-mg oral dose of aripiprazole, decreased the mean AUC and C^ of aripiprazole by 50%.
Hemodialysis: Although there is no information on the effect of hemodialysis in treating an overdose with aripiprazole, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins. 
